Fennec (FENC) Pharmaceuticals announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla’s application to FDA for approval to market a generic version of Fennec’s PEDMARK product. Under the terms of the agreement, the lawsuit will be dismissed with each party bearing their own costs, and Cipla will not enter the market with its generic sodium thiosulfate product until September 1, 2033, or earlier under certain circumstances.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Buy Rating on Fennec Pharmaceuticals Driven by PEDMARK’s Long-Term Adoption Potential, Emerging Japan Upside, and Improving Profitability Supporting a $13 Target
- Fennec, Tampa General launch real-world PEDMARK oncology study
- Fennec announces clinical research collaboration with Tampa General Hospital
- Fennec Showcases Real-World Data Backing PEDMARK Use in Adult Head and Neck Cancer
- Fennec presents real world date on use of Pedmark